Sanctuary Advisors LLC bought a new position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 56,945 shares of the biotechnology company’s stock, valued at approximately $966,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Cvfg LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the 1st quarter valued at approximately $1,000,000. Ritholtz Wealth Management increased its position in Aurinia Pharmaceuticals by 21.5% during the 1st quarter. Ritholtz Wealth Management now owns 314,426 shares of the biotechnology company’s stock worth $4,660,000 after purchasing an additional 55,610 shares in the last quarter. Renaissance Technologies LLC increased its position in Aurinia Pharmaceuticals by 4.6% during the 1st quarter. Renaissance Technologies LLC now owns 1,663,835 shares of the biotechnology company’s stock worth $24,658,000 after purchasing an additional 73,700 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Aurinia Pharmaceuticals in the first quarter valued at approximately $1,340,000. Finally, Rice Hall James & Associates LLC bought a new stake in shares of Aurinia Pharmaceuticals during the second quarter worth $7,070,000. 36.83% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, August 12th. Royal Bank Of Canada raised their price objective on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a report on Friday, August 7th. Zacks Research cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Bloom Burton raised Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Finally, Wall Street Zen lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.67.
Insider Buying and Selling
In other Aurinia Pharmaceuticals news, CEO Kevin Tang bought 206,005 shares of the stock in a transaction on Tuesday, June 2nd. The stock was acquired at an average cost of $15.28 per share, for a total transaction of $3,147,756.40. Following the completion of the acquisition, the chief executive officer owned 13,044,106 shares in the company, valued at $199,313,939.68. This trade represents a 1.60% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 10.40% of the stock is owned by corporate insiders.
Aurinia Pharmaceuticals Stock Performance
Shares of AUPH opened at $16.48 on Friday. The company has a current ratio of 5.42, a quick ratio of 4.97 and a debt-to-equity ratio of 0.07. The firm’s fifty day simple moving average is $15.98 and its two-hundred day simple moving average is $15.49. Aurinia Pharmaceuticals Inc has a 12 month low of $10.34 and a 12 month high of $19.25. The stock has a market capitalization of $2.19 billion, a P/E ratio of 7.20 and a beta of 1.42.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.04. The firm had revenue of $58.57 million during the quarter, compared to analyst estimates of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. As a group, analysts predict that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current year.
Aurinia Pharmaceuticals Profile
Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.
The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.
Featured Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP).
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
